New stem cell shot for osteoarthritis can reduce pain by 58%

Table of Contents

New clinical trial suggests donor stem cell treatment could alleviate knee osteoarthritis symptoms and possibly halting disease progression.

A recent clinical trial conducted by Australian biotechnology firm Magellan Stem Cells has opened new avenues for osteoarthritis treatment, suggesting that stem cell therapy may offer a compelling alternative. The Phase I/II trial assessed the safety and efficacy of MAG200, an off-the-shelf allogeneic (donor) stem cell therapy, on patients suffering from knee osteoarthritis . The results, published in Osteoarthritis and Cartilage Open, indicate that this new treatment could substantially improve joint function, reduce pain and potentially modify the course of the disease [1].

Longevity.Technology: Osteoarthritis (OA) is a progressive joint disorder, recognized as the fourth leading cause of disability worldwide. Affecting over 650 million individuals aged 40 years and above, knee osteoarthritis is associated with increased frailty, and research indicates that frailty may also drive OA development [2]. This chronic condition carries a significant economic and healthcare burden, with total knee replacement (TKR) surgery being the most common treatment when conservative therapies fail. However, TKR has its limitations, with around 20-30% of patients experiencing persistent pain and loss of function post-surgery.

Associate Professor Julien Freitag, the lead researcher of the trial and Magellan Chief Medical Officer, explained that osteoarthritis represents an unmet clinical need as current therapies offer limited pain relief (and may also be associated with significant side effects,) and that the trial results suggest that this therapy could delay or prevent the need for joint replacement surgery.

The trial findings are particularly compelling. Patients receiving MAG200 demonstrated a sustained 58% improvement in pain levels at 12 months, while their quality of life scores more than doubled. Notably, those who received the stem cell treatment showed signs of improved cartilage volume – a marker of disease modification – while the placebo group either remained unchanged or saw their osteoarthritis progress [1]. This trial is one of the first to suggest that a single injection of stem cells could maintain therapeutic benefits beyond four years, marking a significant step forward in OA treatment research.

The implications of these findings are far-reaching. With the growing incidence of OA and increasing rates of joint replacement surgery, the orthopaedic workforce is struggling to meet demand. Studies suggest that the number of orthopedic surgeons will need to increase by 10% every five years to cope with the rising cases of OA [3]. Given these pressures, therapies that could delay or prevent TKR would alleviate both the clinical and economic burden associated with OA.

Current intra-articular (IA) therapies, such as corticosteroids and hyaluronic acid injections, offer only temporary relief and are not linked to disease modification – mesenchymal stem cells (MSCs), on the other hand, have emerged as a promising alternative. MSCs can differentiate into various cell types, including chondrocytes, the main component of cartilage, which are essential for cartilage repair and are responsible for its structure, maintenance and flexibility Furthermore, chondrocytes modulate inflammation by suppressing pro-inflammatory cytokines and promoting tissue repair, making them an attractive option for OA treatment.

Associate Professor Julien Freitag, lead researcher of the trial and Magellan Chief Medical Officer

“Magellan’s off-the-shelf donor stem cell treatment is safe and effective in improving joint function, reducing pain levels, and may have the potential to halt the progression of osteoarthritis,” said Associate Professor Freitag [4]. The trial not only highlighted the efficacy of MSCs but also demonstrated their safety, with no treatment-related serious adverse events reported [1].

The development of an allogeneic MSC therapy such as Magellan’s MAG200 offers several advantages over autologous MSC treatments, which require harvesting stem cells from the patient’s own body. Autologous therapies are labor-intensive, expensive and involve surgical procedures, limiting their accessibility. In contrast, allogeneic preparations are scalable and ready for use without the need for patient-specific customization. Importantly, MSCs are considered immune-evasive, meaning they can be safely used in genetically unmatched recipients.

Despite these promising results, more research is needed to confirm MAG200’s long-term efficacy and safety. The current study was limited by its early-phase nature, and while trends in disease modification were observed, the results were not statistically significant. Nevertheless, the trial provides strong evidence to justify further late-stage research.

Associate Professor Freitag expressed optimism about the future of stem cell therapies for OA. “I believe our research results represent a pivotal moment for the management of osteoarthritis and may change the way we practice medicine in the future,” he said. “Cell therapies, including Magellan’s donor stem cell treatment, is a promising and rapidly advancing field with a potential to transform medical management of conditions which currently have limited treatment options [4].”

Magellan Stem Cells’ Head Scientific Officer, Dr Kiran Shah, echoed these sentiments, emphasizing the importance of local innovation. “We are excited to have been able to develop a world-leading cell therapy within Australia,” Shah said [4]. The development of MAG200 highlights Australia’s investment in advanced medical technologies, reducing reliance on offshore manufacturing and therapeutic development.

With the global burden of osteoarthritis set to rise, the introduction of a scalable, disease-modifying therapy like MAG200 could have a significant impact on millions of sufferers worldwide. If future research continues to support these early findings, donor stem cell therapy may soon become a cornerstone in the fight against this debilitating condition.